-
Vascular Health and Risk Management
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Cardiovascular disease in patients with chronic kidney disease
Review
(5209) Views (1671) Full article downloads
Authors: Julian Wright, Alastair Hutchison
Published Date August 2009
Volume 2009:5 Pages 713 - 722
DOI: http://dx.doi.org/10.2147/VHRM.S6206
Julian Wright, Alastair Hutchison
Manchester Institute of Nephrology and Transplantation, Manchester Royal Infirmary, Manchester, UK
Abstract: Patients with chronic kidney disease have a high burden of cardiovascular morbidity and mortality. The vast majority of patients with chronic kidney disease do not progress to end stage renal failure, but do have a significantly higher incidence of all cardiovascular co-morbidities. Traditional cardiovascular risk factors only partially account for this increased incidence of cardiovascular disease. In patients with kidney disease the basic biology underlying cardiovascular disease may be similar to that in patients without kidney disease, but it would seem many more risk factors are involved as a consequence of renal dysfunction. Although emphasis is placed on delaying the progression of chronic kidney disease, it must be appreciated that for many patients it is vital to address their cardiovascular risk factors at an early stage to prevent premature cardiovascular death. This review examines available epidemiological evidence, discusses common cardiovascular risk factors in patients with chronic kidney disease, and suggests possible treatment strategies. Potential areas for important research are also described.
Keywords: cardiovascular risk factors, chronic kidney disease, hypertension, diabetes
Other articles by Dr Alistair Hutchison
Readers of this article also read:
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure
Cardiac risk stratification: Role of the coronary calcium score
Estimating glomerular filtration rate in a population-based study
A case of recurrent bloody tears
Erratum
Effect of vascular burden as measured by vascular indexes upon vascular dementia: a matched case-control study
Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
- Join ISVH
Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- The western diet and lifestyle and diseases of civilization
- Stiffness of the large arteries in individuals with and without Down syndrome
- Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study
- Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review




